A citation-based method for searching scientific literature

Mark A Socinski, Nathan A Pennell, Kurtis D Davies. JCO Precis Oncol 2021
Times Cited: 20







List of co-cited articles
122 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
Jürgen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B Garon, Harry J M Groen, Daniel S W Tan, Toyoaki Hida, Maja de Jonge, Sergey V Orlov,[...]. N Engl J Med 2020
287
50

Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Marina C Garassino, Julien Mazieres, Santiago Viteri, Helene Senellart, Jan Van Meerbeeck,[...]. N Engl J Med 2020
261
45

MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
Mark M Awad, Geoffrey R Oxnard, David M Jackman, Daniel O Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C Heng, Suzanne E Dahlberg, Pasi A Jänne, Suman Verma,[...]. J Clin Oncol 2016
390
45

MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Joanna H Tong, Sai F Yeung, Anthony W H Chan, Lau Y Chung, Shuk L Chau, Raymond Wai Ming Lung, Carol Y Tong, Chit Chow, Edith K Y Tin, Yau H Yu,[...]. Clin Cancer Res 2016
253
35

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Alexander Drilon, Jeffrey W Clark, Jared Weiss, Sai-Hong Ignatius Ou, D Ross Camidge, Benjamin J Solomon, Gregory A Otterson, Liza C Villaruz, Gregory J Riely, Rebecca S Heist,[...]. Nat Med 2020
159
35

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Garrett M Frampton, Siraj M Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M Bauer, Mikhail Akimov, Jose A Bufill, Carrie Lee, David Jentz,[...]. Cancer Discov 2015
473
35

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Alexa B Schrock, Garrett M Frampton, James Suh, Zachary R Chalmers, Mark Rosenzweig, Rachel L Erlich, Balazs Halmos, Jonathan Goldman, Patrick Forde, Kurt Leuenberger,[...]. J Thorac Oncol 2016
208
30


Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study.
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang,[...]. Lancet Respir Med 2021
38
30

MET-dependent solid tumours - molecular diagnosis and targeted therapy.
Robin Guo, Jia Luo, Jason Chang, Natasha Rekhtman, Maria Arcila, Alexander Drilon. Nat Rev Clin Oncol 2020
79
30

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis.
Huy Gia Vuong, An Thi Nhat Ho, Ahmed M A Altibi, Tadao Nakazawa, Ryohei Katoh, Tetsuo Kondo. Lung Cancer 2018
61
30

Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer.
Lingzhi Hong, Jianjun Zhang, John V Heymach, Xiuning Le. Ther Adv Med Oncol 2021
18
27

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paul K Paik, Alexander Drilon, Pang-Dian Fan, Helena Yu, Natasha Rekhtman, Michelle S Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F Berger, Charles M Rudin,[...]. Cancer Discov 2015
412
25

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
J K Sabari, G C Leonardi, C A Shu, R Umeton, J Montecalvo, A Ni, R Chen, J Dienstag, C Mrad, I Bergagnini,[...]. Ann Oncol 2018
156
25

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
F Mosele, J Remon, J Mateo, C B Westphalen, F Barlesi, M P Lolkema, N Normanno, A Scarpa, M Robson, F Meric-Bernstam,[...]. Ann Oncol 2020
289
20

Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Monica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, Wenjing Zhu, Kaumudi Bhawe, Nerissa Mendoza, Thomas Holcomb, Kanan Pujara, Jeremy Stinson, Ling Fu,[...]. Cancer Res 2006
352
20

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Xuewen Liu, Yuxia Jia, Mark B Stoopler, Yufeng Shen, Haiying Cheng, Jinli Chen, Mahesh Mansukhani, Sanjay Koul, Balazs Halmos, Alain C Borczuk. J Clin Oncol 2016
224
20

Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based Sequencing.
Ziguang Xu, Hongxia Li, Yujie Dong, Peng Cheng, Fang Luo, Shijun Fu, Min Gao, Lingfei Kong, Nanying Che. Onco Targets Ther 2020
16
25

Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Gonzalo Recondo, Magda Bahcall, Liam F Spurr, Jianwei Che, Biagio Ricciuti, Giulia C Leonardi, Ying-Chun Lo, Yvonne Y Li, Giuseppe Lamberti, Tom Nguyen,[...]. Clin Cancer Res 2020
77
20

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.
Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F Vansteenkiste, Wu-Chou Su, Enriqueta Felip,[...]. J Clin Oncol 2018
168
20

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
474
20

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Lecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, Byoung Chul Cho, Helena Yu, Sang-We Kim, James Chih-Hsin Yang, Jong Seok Lee, Wu-Chou Su, Dariusz Kowalski,[...]. Lancet Oncol 2020
184
20

DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Kurtis D Davies, Aprille Lomboy, Carolyn A Lawrence, Michael Yourshaw, Gregary T Bocsi, D Ross Camidge, Dara L Aisner. J Thorac Oncol 2019
66
20

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
Rebecca S Heist, Hyo Sup Shim, Shalini Gingipally, Mari Mino-Kenudson, Long Le, Justin F Gainor, Zongli Zheng, Martin Aryee, Junfeng Xia, Peilin Jia,[...]. Oncologist 2016
71
15


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
15

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
David R Spigel, Thomas J Ervin, Rodryg A Ramlau, Davey B Daniel, Jerome H Goldschmidt, George R Blumenschein, Maciej J Krzakowski, Gilles Robinet, Benoit Godbert, Fabrice Barlesi,[...]. J Clin Oncol 2013
374
15

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Jeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, Youngchul Song, Courtney Hyland, Joon Oh Park, Neal Lindeman, Christopher-Michael Gale, Xiaojun Zhao, James Christensen,[...]. Science 2007
15

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
Nadia Howlader, Gonçalo Forjaz, Meghan J Mooradian, Rafael Meza, Chung Yin Kong, Kathleen A Cronin, Angela B Mariotto, Douglas R Lowy, Eric J Feuer. N Engl J Med 2020
416
15

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.
Ferdinandos Skoulidis, Michael E Goldberg, Danielle M Greenawalt, Matthew D Hellmann, Mark M Awad, Justin F Gainor, Alexa B Schrock, Ryan J Hartmaier, Sally E Trabucco, Laurie Gay,[...]. Cancer Discov 2018
742
15

Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.
M Schuler, R Berardi, W-T Lim, M de Jonge, T M Bauer, A Azaro, M Gottfried, J-Y Han, D H Lee, M Wollner,[...]. Ann Oncol 2020
43
15

Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Sinéad A Noonan, Lynne Berry, Xian Lu, Dexiang Gao, Anna E Barón, Patrick Chesnut, Jamie Sheren, Dara L Aisner, Dan Merrick, Robert C Doebele,[...]. J Thorac Oncol 2016
105
15

Efficacy of pembrolizumab for patients with both high PD-L1 expression and an MET exon 14 skipping mutation: A case report.
Keisuke Baba, Hisashi Tanaka, Hiroaki Sakamoto, Toshihiro Shiratori, Junichiro Tsuchiya, Yoshiko Ishioka, Masamichi Itoga, Kageaki Taima, Sadatomo Tasaka. Thorac Cancer 2019
10
30

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations.
Mariacarmela Santarpia, Marco Massafra, Vittorio Gebbia, Antonio D'Aquino, Claudia Garipoli, Giuseppe Altavilla, Rafael Rosell. Transl Lung Cancer Res 2021
9
33

MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
F Cappuzzo, P A Jänne, M Skokan, G Finocchiaro, E Rossi, C Ligorio, P A Zucali, L Terracciano, L Toschi, M Roncalli,[...]. Ann Oncol 2009
247
15

MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
Henning Reis, Martin Metzenmacher, Moritz Goetz, Nikoleta Savvidou, Kaid Darwiche, Clemens Aigner, Thomas Herold, Wilfried E Eberhardt, Charlotte Skiba, Jörg Hense,[...]. Clin Lung Cancer 2018
43
15

Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung.
David R Spigel, Martin J Edelman, Kenneth O'Byrne, Luis Paz-Ares, Simonetta Mocci, See Phan, David S Shames, Dustin Smith, Wei Yu, Virginia E Paton,[...]. J Clin Oncol 2017
185
15

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.
Yiting Dong, Jiachen Xu, Boyang Sun, Jie Wang, Zhijie Wang. Mol Diagn Ther 2022
5
60

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.
Lun-Xi Peng, Guang-Ling Jie, An-Na Li, Si-Yang Liu, Hao Sun, Mei-Mei Zheng, Jia-Ying Zhou, Jia-Tao Zhang, Xu-Chao Zhang, Qing Zhou,[...]. Exp Hematol Oncol 2021
7
42

Crizotinib in ROS1-rearranged non-small-cell lung cancer.
Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa,[...]. N Engl J Med 2014
15


The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
Si-Yang Liu, Lan-Ying Gou, An-Na Li, Na-Na Lou, Hong-Fei Gao, Jian Su, Jin-Ji Yang, Xu-Chao Zhang, Yang Shao, Zhong-Yi Dong,[...]. J Thorac Oncol 2016
46
15

MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-Bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song,[...]. J Thorac Oncol 2017
57
15

FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, Pourab Roy, Anup K Amatya, Mallorie H Fiero, Pallavi S Mishra-Kalyani, Whitney S Helms, Claire E Myers, Amy M Skinner,[...]. Clin Cancer Res 2022
18
16

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip. Cancer Treat Rev 2020
39
15

Molecular profiling for precision cancer therapies.
Eoghan R Malone, Marc Oliva, Peter J B Sabatini, Tracy L Stockley, Lillian L Siu. Genome Med 2020
218
15

Crizotinib in Patients With MET-Amplified NSCLC.
D Ross Camidge, Gregory A Otterson, Jeffrey W Clark, Sai-Hong Ignatius Ou, Jared Weiss, Steven Ades, Geoffrey I Shapiro, Mark A Socinski, Danielle A Murphy, Umberto Conte,[...]. J Thorac Oncol 2021
31
15

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Robin Guo, Lynne D Berry, Dara L Aisner, Jamie Sheren, Theresa Boyle, Paul A Bunn, Bruce E Johnson, David J Kwiatkowski, Alexander Drilon, Lynette M Sholl,[...]. J Thorac Oncol 2019
61
15

Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Eun Kyung Kim, Kyung A Kim, Chang Young Lee, Sangwoo Kim, Sunhee Chang, Byoung Chul Cho, Hyo Sup Shim. Clin Lung Cancer 2019
43
10

MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Raphaël Saffroy, Vincent Fallet, Nicolas Girard, Julien Mazieres, Denis Moro Sibilot, Sylvie Lantuejoul, Isabelle Rouquette, Françoise Thivolet-Bejui, Thibaut Vieira, Martine Antoine,[...]. Oncotarget 2017
30
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.